WuXi AppTec: company raises continuous operations revenue growth forecast from 10-15% to 13-17%

WuXi AppTec: company raises continuous operations revenue growth forecast from 10-15% to 13-17%

WuXi AppTec, a leading provider of drug discovery and development services, has revised its continuous operations revenue growth forecast for the year. The company now expects revenue to grow between 13% and 17%, up from its previous outlook of 10% to 15% [1].

The upward revision in the revenue growth forecast is driven by strong performance in its drug discovery and development services, as well as its contract research organization (CRO) segment. The company reported robust demand for its services, particularly in the areas of drug discovery and development, and contract manufacturing.

WuXi AppTec also highlighted its strategic investments in new technologies and capabilities, which are expected to drive growth in the coming quarters. The company's focus on innovation and its ability to adapt to changing market conditions have been key factors in its success.

Despite the positive outlook, WuXi AppTec faces several challenges, including geopolitical uncertainties and potential disruptions in the global supply chain. The company is closely monitoring these factors and has implemented measures to mitigate risks.

The revised revenue growth forecast comes as WuXi AppTec continues to expand its global footprint and strengthen its market position. The company's ability to deliver consistent growth in a challenging environment underscores its resilience and strategic agility.

References

[1] https://finance.yahoo.com/news/wuxi-apptec-raises-continuous-operations-revenue-growth-forecast-072342527.html